Characterization and transcriptome analysis of mycobacterium tuberculosis persisters

mBio

Volumn 2, Issue 3, 2011, Pages

  Keren, Iris ^a   Minami, Shoko ^b,c   Rubin, Eric ^b,c   Lewis, Kim ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CYCLOSERINE; ISONIAZID; RIBOSOME PROTEIN; RIFAMPICIN; STREPTOMYCIN; TRANSCRIPTOME; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BIOSYNTHESIS; CENTRIFUGATION; CONCENTRATION RESPONSE; CYTOLYSIS; DORMANCY; DOWN REGULATION; DRUG TOLERANCE; GENE NUMBER; IN VITRO STUDY; MICROARRAY ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; RNA HYBRIDIZATION; TRANSCRIPTOMICS; UPREGULATION; BACTERIAL GENE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIOLOGY; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DOWN-REGULATION; DRUG TOLERANCE; GENE EXPRESSION PROFILING; GENES, BACTERIAL; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICROARRAY ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; UP-REGULATION;

EID: 84855195248     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00100-11     Document Type: Article

References (60)

1. Comroe JH, Jr. 1978. Pay dirt: the story of streptomycin. Part 1. From Waksman to Waksman. Am. Rev. Respir. Dis. 117:773-781.
2. WHO. 2010. Global tuberculosis control 2010, vol. 218. World Health Organization, Geneva, Switzerland.
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677-686.
4. Leung CC, Rieder HL, Lange C, Yew WW. 2011. Series ''update on tuberculosis'': treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur. Respir. J. 37:690-711.
5. Davies PD. 2001. Drug-resistant tuberculosis. J. R. Soc. Med. 94:261-263.
6. Mendoza MT, et al. 1997. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines. Int. J. Tuberc. Lung Dis. 1:59-63.
7. Unoson C, Wagner EG. 2008. A small SOS-induced toxin is targeted against the inner membrane in Escherichia coli. Mol. Microbiol. 70: 258-270.
8. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55:139-163.
9. Garton NJ, Waddell SJ, Sherratt AL, et al. 2008. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 5:e75.
10. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
11. Connolly LE, Edelstein PH, Ramakrishnan L. 2007. Why is long-term therapy required to cure tuberculosis? PLoS Med. 4:e120.
12. Barry CE, et al. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-855.
13. Bentrup K, Russell D. 2001. Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol. 9:597-605.
14. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 3:e1502.
15. Voskuil MI, Visconti KC, Schoolnik GK. 2004. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and lowoxygen dormancy. Tuberculosis (Edinb) 84:218-227.
16. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43: 717-731.
17. Voskuil MI, et al. 2003. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198: 705-713.
18. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372.
19. Bigger J. 1944. Treatment of staphylococcal infections with penicillin. Lancet 244:497-500.
20. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230:13-18.
21. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625.
22. Shah D, et al. 2006. Persisters: a distinct physiological state of E. coli. BMC Microbiol. 6:53-62.
23. Moyed HS, Broderick SH. 1986. Molecular cloning and expression of hipA, a gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J. Bacteriol. 166:399-403.
24. Moyed HS, Bertrand KP. 1983. Hipa, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J. Bacteriol. 155:768-775.
25. Schumacher MA, et al. 2009. Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. Science 323:396-401.
26. Correia FF, et al. 2006. Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. J. Bacteriol. 188:8360-8367.
27. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. 2004. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 186:8172-8180.
28. Vázquez-Laslop N, Lee H, Neyfakh AA. 2006. Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J. Bacteriol. 188: 3494-3497.
29. Singh R, Barry CE, Boshoff HI. 2010. The three relE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J. Bacteriol. 192:1279-1291.
30. Alix E, Blanc-Potard AB. 2009. Hydrophobic peptides: novel regulators within bacterial membrane. Mol. Microbiol. 72:5-11.
31. Tsilibaris V, Maenhaut-Michel G, Mine N, Van Melderen L. 2007. What is the benefit to Escherichia coli of having multiple toxin-antitoxin systems in its genome? J. Bacteriol. 189:6101-6108.
32. Pandey DP, Gerdes K. 2005. Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. Nucleic Acids Res. 33:966-976.
33. Hansen S, Lewis K, Vulić M. 2008. Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob. Agents Chemother. 52:2718-2726.
34. Hu Y, Coates AR. 2005. Transposon mutagenesis identifies genes which control antimicrobial drug tolerance in stationary-phase Escherichia coli. FEMS Microbiol. Lett. 243:117-124.
35. Dörr T, Vulić M, Lewis K. 2010. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8:e1000317.
36. Dörr T, Lewis K, Vulić M. 2009. SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet. 5:e1000760.
37. Vogel J, Argaman L, Wagner EG, Altuvia S. 2004. The small RNA IstR inhibits synthesis of an sos-induced toxic peptide. Curr. Biol. 14: 2271-2276.
38. Lewis K. 2005. Persister cells and the riddle of biofilm survival. Biochem. Mosc. 70:267-274.
39. Tudo G, Laing K, Mitchison DA, Butcher PD, Waddell SJ. 2010. Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling. Future Med. Chem. 2:1371-1383.
40. Falkinham JO, Crawford JT. 1994. Plasmids, p. 185-198. In Bloom BR (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, DC.
41. Cole ST. 2002. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 148:2919-2928.
42. Cox RA, Cook GM. 2007. Growth regulation in the mycobacterial cell. Curr. Mol. Med. 7:231-245.
43. Wayne LG, Lin KY. 1982. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect. Immun. 37:1042-1049.
44. Muñoz-Elías EJ, McKinney JD. 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 11:638-644.
45. Ramage HR, Connolly LE, Cox JS. 2009. Comprehensive functional analysis of Mycobacterium tuberculosis toxin-antitoxin systems: implications for pathogenesis, stress responses, and evolution. PLoS Genet. 5:e1000767.
46. Drumm JE, et al. 2009. Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by atp-binding: requirement for establishing chronic persistent infection. PLoS Pathog. 5:e1000460.
47. Canetti GJ. 1955. The tubercle bacillus in the pulmonary lesion of man. The histobacteriogenesis of tuberculous lesion: experimental studies. Spring Publishing Company, New York, NY.
48. Lillebaek T, et al. 2002. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185:401-404.
49. Shapiro JA, Nguyen VL, Chamberlain NR. 2011. Evidence for persisters in Staphylococcus epidermidis RP62a planktonic cultures and biofilms. J. Med. Microbiol. [Epub ahead of print.] doi: 10.1099/jmm.0.029013-0.
50. Mccune RM, Tompsett R. 1956. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737-762.
51. Ahmad Z, et al. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200:1136-1143.
52. Jindani A, Doré CJ, Mitchison DA. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354.
53. Herbert D, Paramasivan CN, Venkatesan P, et al. 1996. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2296-2299.
54. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. 2005. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:627-631.
55. Park HD, et al. 2003. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol. Microbiol. 48: 833-843.
56. Chen P, Ruiz RE, Li Q, Silver RF, Bishai WR. 2000. Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect. Immun. 68:5575-5580.
57. Boshoff HI, Reed MB, Barry CE, Mizrahi V. 2003. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113:183-193.
58. Desjardin LE, Hayes LG, Sohaskey CD, Wayne LG, Eisenach KD. 2001. Microaerophilic induction of the alpha-crystallin chaperone protein homologue (hspX) mRNA of Mycobacterium tuberculosis. J. Bacteriol. 183: 5311-5316.
59. Lee JH, Geiman DE, Bishai WR. 2008. Role of stress response sigma factor SigG in Mycobacterium tuberculosis. J. Bacteriol. 190:1128-1133.
60. Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315.